Xbrane Biopharma AB ( (SE:XBRANE) ) just unveiled an update.
Xbrane Biopharma AB’s annual general meeting resulted in several key resolutions, including the adoption of the income statement and balance sheet, the decision not to distribute dividends, and the re-election of board members and auditors. The meeting also established remuneration for directors and committee members and set guidelines for senior executive remuneration, while withdrawing a proposal for issuing shares due to insufficient support.
More about Xbrane Biopharma AB
Xbrane Biopharma AB operates in the biotechnology industry, focusing on developing and manufacturing biosimilar drugs. The company aims to provide affordable and effective treatments, primarily targeting markets with high medical needs.
Average Trading Volume: 13,361,985
Current Market Cap: SEK293.3M
See more insights into XBRANE stock on TipRanks’ Stock Analysis page.